<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01221545</url>
  </required_header>
  <id_info>
    <org_study_id>D1020C00044</org_study_id>
    <nct_id>NCT01221545</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients</brief_title>
  <official_title>A Randomised, Single-Blind, Placebo-Controlled, Single-Centre Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After High Single Ascending Oral Supratherapeutic Doses of AZD1656 in Male Type 2 Diabetes Mellitus (T2DM) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate safety and tolerability after high Single
      Ascending Oral Doses of AZD1656.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Objective to assess the safety and tolerability of AZD1656, following oral administration of single ascending supratherapeutic doses of AZD1656 to patients with type 2 diabetes mellitus in a fasted state.</measure>
    <time_frame>From screening until Follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary objective to evaluate the pharmacokinetics (AUC, Cmax, t1/2, CL/F) of AZD1656 and its metabolite following oral administration of single ascending supratherapeutic doses of AZD1656</measure>
    <time_frame>From pre-dose Day 1 to 48 hours after dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary objective to evaluate glucose levels and insulin secretion in type 2 diabetes mellitus patients following oral administration of single ascending supratherapeutic doses of AZD1656</measure>
    <time_frame>Glucose levels from Day -1 to day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary objective to evaluate glucose levels and insulin secretion in type 2 diabetes mellitus patients following oral administration of single ascending supratherapeutic doses of AZD1656</measure>
    <time_frame>Insuline secretion from Day -1 to 2.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>A - AZD1656</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1656</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1656</intervention_name>
    <description>3 escalating dose levels are planned. Administration of the escalating doses of AZD1656 will be based on review of available safety from the previous dose.</description>
    <arm_group_label>A - AZD1656</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>B - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures.

          -  Male, T2DM patients aged 20-60 years

          -  Treatment with 1 to 2 OADs as Therapy for T2DM for at least 30 days prior to
             enrollment

          -  Patients should not have been treated with glitazones within 6 months prior to
             enrollment

          -  Male T2DM patients without known cardiovascular disease, with the exception of Grade 1
             hypertension without secondary organ involvement (eg. grade 1 HT is allowed if no eye,
             kidney disease or LVH has been documented).

        Exclusion Criteria:

          -  History of ischemic heart disease , heart failure, stroke, transitory ischemic attack
             or peripheral vascular disease.

          -  Prolonged QTcF&gt;450 msec or shortened QTcF&lt;350 msec or family history of long QT
             syndrome.

          -  Any clinically important abnormalities in rhythm, conduction or morphology of resting
             ECG that may interfere with the interpretation of QTc interval changes.

          -  Systolic BP&gt;159 mmHg or diastolic BP&gt;99 mmHg at screening and on Day-1
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda Morrow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institute for Clinical Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2010</study_first_submitted>
  <study_first_submitted_qc>October 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2010</study_first_posted>
  <last_update_submitted>February 16, 2011</last_update_submitted>
  <last_update_submitted_qc>February 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Eva Johnsson MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

